



*Press release*

*Stockholm, October 22, 2009*

## Interim Report – January to September 2009

Affibody Holding AB (publ) (“Affibody” or “the Company”), a Swedish biotech company focused on developing next generation products for therapy, diagnostic imaging, and other applications based on its unique proprietary technology platforms: Affibody® molecules and Albumod™, today issued its Interim Report covering the nine-month period ended September 30, 2009.

### Financial Highlights

- Revenue for the the first nine months of 2009 was SEK 19.0 (19.8) million
- Net loss for the period amounted to SEK –19.0 (-74.9) million
- Earnings per share was SEK –0.42 (-2.50)
- Cash flow from current operations was SEK –31.4 (-58.9) million
- SEK 36.4m raised in additional financing of which 20.2m in cash

### Key Corporate Highlights

- A collaboration agreement has been signed with Biovitrum AB with the aim of developing new targeted therapeutics for inflammation and autoimmune diseases. This is in line with Affibody’s new strategy, aiming to generate profitable corporate partnerships across the life science sector based on its unique proprietary technology platforms: Affibody® molecules and Albumod™ and designed to allow Affibody to reach its key corporate objective of sustainable profitability in the next two years.
- During the period, Affibody obtained the third and final approval required to commence a Phase I study in Germany with its lead molecular imaging agent, ABY-025, which is based on a highly specific Affibody® molecule that binds the breast cancer marker HER2.
- Affibody’s proprietary albumin binding technology, Albumod™, has gained interest from several companies searching for a relevant drug development technology.
- Affibody has obtained approval to commence an exploratory clinical study regarding bladder cancer in Uppsala.
- Half-life extension of ten times has been demonstrated *in vivo* by applying the Albumod™ platform to G-CSF (more information can be found at [http://www.affibody.se/en/Product-Portfolio/The\\_Albumin\\_Binding\\_Technology/Results/](http://www.affibody.se/en/Product-Portfolio/The_Albumin_Binding_Technology/Results/)).

David Bejker CEO, said: “*Affibody has during the first nine months of 2009 continued to deliver on the plan that was launched late last year. The first results from our internal Albumod™ project have been generated according to plan and we expect to continue to generate interesting results from this program.*”

### Enquiries

David Bejker, CEO  
Johan Stuart CFO

+46 706 454 948

+46 706 644 096

## About Affibody

Affibody is a Swedish biotech company focused on developing next generation products for therapy, diagnostic imaging, and other applications based on its unique proprietary technology platforms: Affibody® molecules and Albumod™.

Affibody® molecules, which are small, robust and easily produced, can be designed to bind specifically to a large number of target proteins. They have a broad range of applications including protein purification, enzyme inhibition, research reagents for protein capture and detection, diagnostics, including molecular imaging, and targeted therapeutics.

Affibody is also commercializing Albumod™, a unique albumin binding technology designed to enhance the efficacy of biotherapeutics by extending their circulation time.

Affibody has already developed biotechnological products that are commercialized by GE, Agilent and Finnzymes, and is developing molecules for therapeutic application in collaboration with Biovitrum.

Affibody was founded in 1998 by researchers from the Royal Institute of Technology and the Karolinska Institute and is based in Stockholm, Sweden. Major shareholders in the Company include the investment companies HealthCap and Investor Growth Capital.

Further information can be found at: [www.affibody.com](http://www.affibody.com)

*Statements in this press release that are not strictly historical may be forward-looking and include risks and uncertainties. Therefore, though based on Affibody's current expectations, it should be duly noted that a variety of factors could cause actual results and experiences to differ materially from what is herein expressed. Risks and uncertainties include, but are not limited to, risks associated with the management of growth and international operations (including effects of currency fluctuations), variability of operating results, unforeseen changes in the diagnostic and pharmaceutical markets, market competition, rapid or unexpected changes in technologies, fluctuations in product demand, difficulties to successfully develop, adapt, produce or commercialize products, the ability to identify and develop new products and to differentiate products from those of competitors, future capital needs and the uncertainty of additional funding, as well as various legal hazards.*



Voltavägen 13, P.O. Box 20137, SE-161 02 Bromma, Sweden.  
Tel +46 8 59 88 38 00, Fax +46 8 59 88 38 01, [www.affibody.com](http://www.affibody.com)